SF 4875
Introduction - 94th Legislature (2025 - 2026)
Posted on 03/27/2026 09:15 a.m.
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10
3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 3.31 3.32 4.1 4.2
4.3 4.4 4.5 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 4.31
A bill for an act
relating to cannabis; modifying requirements for the medical cannabis endorsement;
amending Minnesota Statutes 2024, section 342.51, subdivisions 1, 3; Minnesota
Statutes 2025 Supplement, section 342.51, subdivision 2.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1.
Minnesota Statutes 2024, section 342.51, subdivision 1, is amended to read:
Subdivision 1.
Endorsement; authorized actions.
(a) The office may issue a medical
cannabis endorsement to a cannabis business authorizing the business to:
(1) cultivate medical cannabis;
(2) process medical cannabinoid products; or
(3) sell or distribute medical cannabis flower and medical cannabinoid products to any
person authorized to receive medical cannabis flower or medical cannabinoid products.
(b) The office must issue a medical cannabis cultivation endorsement to a cannabis
license holder if the license holder:
(1) is authorized to cultivate cannabis;
(2) submits a medical cannabis endorsement application to the office; and
(3) otherwise meets all applicable requirements established by the office.
(c) A medical cannabis cultivation endorsement entitles the license holder to grow
cannabis plants within the approved amount of space from seed or immature plant to mature
plant, harvest cannabis flower from a mature plant, package and label cannabis flower as
medical cannabis flower, sell medical cannabis flower to cannabis businesses with a medical
cannabis endorsement, and perform other actions approved by the office.
(d) The office must issue a medical cannabis processor endorsement to a cannabis license
holder if the license holder:
(1) is authorized to manufacture cannabis products;
(2) submits a medical cannabis endorsement application to the office; and
(3) otherwise meets all applicable requirements established by the office.
(e) A medical cannabis processor endorsement entitles the license holder to:
(1) purchase medical cannabis flower, medical cannabinoid products, hemp plant parts,
and hemp concentrate from cannabis businesses with a medical cannabis cultivator
endorsement or a medical cannabis processor endorsement;
(2) purchase hemp plant parts from industrial hemp growers;
(3) make cannabis concentrate from medical cannabis flower;
(4) make hemp concentrate, including hemp concentrate with a delta-9
tetrahydrocannabinol concentration of more than 0.3 percent as measured by weight;
(5) manufacture medical cannabinoid products;
(6) package and label medical cannabinoid products for sale to cannabis businesses with
a medical cannabis processer endorsement or a medical cannabis retailer endorsement; and
(7) perform other actions approved by the office.
(f) The office must issue a medical cannabis retailer endorsement to a cannabis license
holder if the license holder:
(1) submits a medical cannabis retail endorsement application to the office;
(2) deleted text begin has at least one employee who earneddeleted text end new text begin identifiesnew text end a medical cannabis consultant new text begin who
has a new text end certificate issued by the office and has completed the required training or deleted text begin has at least
one employee whodeleted text end is a licensed pharmacist under chapter 151new text begin who the license holder employs
or contracts with to consult and provide final authorization for a person enrolled in the
registry programnew text end ; and
(3) otherwise meets all applicable requirements established by the office.
(g) A medical cannabis retail endorsement entitles the license holder to purchase medical
cannabis flower and medical cannabinoid products from cannabis businesses with medical
cannabis cultivator endorsements and medical cannabis processor endorsements, and sell
or distribute medical cannabis flower, medical cannabinoid products, and associated
paraphernalia to any person authorized to receive medical cannabis flower or medical
cannabinoid products.
(h) A medical cannabis business with a medical cannabis retail endorsement must verify
that all medical cannabis flower and medical cannabinoid products have passed safety,
potency, and consistency testing at a cannabis testing facility approved by the office for the
testing of medical cannabis flower and medical cannabinoid products before the cannabis
business with a medical cannabis retail endorsement may distribute the medical cannabis
flower or medical cannabinoid product to any person enrolled in the registry program.
Sec. 2.
Minnesota Statutes 2025 Supplement, section 342.51, subdivision 2, is amended
to read:
Subd. 2.
Distribution requirements.
(a) Prior to distribution of medical cannabis flower
or medical cannabinoid products to a person enrolled in the registry program, an employee
of a cannabis business must:
(1) review and confirm the patient's enrollment in the registry program;
(2) verify that the person requesting the distribution of medical cannabis flower or
medical cannabinoid products is the patient, the patient's registered designated caregiver,
or the patient's parent, legal guardian, or spouse using the procedures established by the
office;
(3) confirm that the patient had a consultation with (i) deleted text begin an employee with a validdeleted text end new text begin anew text end medical
cannabis consultant new text begin who has a valid new text end certificate issued by the office; or (ii) deleted text begin an employee who
isdeleted text end a licensed pharmacist under chapter 151 to determine the proper medical cannabis flower
or medical cannabinoid product, dosage, and paraphernalia for the patient if required under
subdivision 3;
(4) apply a patient-specific label on the medical cannabis flower or medical cannabinoid
product that includes recommended dosage requirements and other information as required
by the office; and
(5) provide the patient with any other information required by the office.
(b) A cannabis business with a medical cannabis retail endorsement may not deliver
medical cannabis flower or medical cannabinoid products to a person enrolled in the registry
program unless the cannabis business with a medical cannabis retail endorsement also holds
a cannabis delivery service license. The delivery of medical cannabis flower and medical
cannabinoid products are subject to the provisions of section 342.42.
Sec. 3.
Minnesota Statutes 2024, section 342.51, subdivision 3, is amended to read:
Subd. 3.
Final approval for distribution of medical cannabis flower and medical
cannabinoid products.
(a) deleted text begin A cannabis worker who is employed by a cannabis business
with a medical cannabis retail endorsement who is licensed as a pharmacist pursuant to
chapter deleted text end deleted text begin 151deleted text end deleted text begin or certified as a medical cannabis consultant by the office is the only person
who may givedeleted text end Final approval for the distribution of medical cannabis flower and medical
cannabinoid productsdeleted text begin . Prior to the distribution of medical cannabis flower or medical
cannabinoid products, a pharmacist or certified medical cannabis consultant employed by
the cannabis business with a medical cannabis retail endorsement must consultdeleted text end new text begin may only
be given by a licensed pharmacist under chapter 151 or a medical cannabis consultant who
has a certificate issued by the office after consultationnew text end with the patient to determine the
proper type of medical cannabis flower, medical cannabinoid product, or medical cannabis
paraphernalia, and the proper dosage for the patient after reviewing the range of chemical
compositions of medical cannabis flower or medical cannabinoid product intended for
distribution:
(1) if the patient is purchasing the medical cannabis flower or medical cannabinoid
product for the first time;
(2) if the patient purchases medical cannabis flower or a medical cannabinoid product
that the patient must administer using a different method than the patient's previous method
of administration;
(3) if the patient purchases medical cannabis flower or a medical cannabinoid product
with a cannabinoid concentration of at least double the patient's prior dosage; or
(4) upon the request of the patient.
(b) For purposes of this subdivision, a consultation may be conducted remotely by secure
videoconference, telephone, or other remote means, as long as:
(1) the pharmacist or consultant engaging in the consultation is able to confirm the
identity of the patient; and
(2) the consultation adheres to patient privacy requirements that apply to health care
services delivered through telemedicine.